OXB.L - Oxford BioMedica PLC

LSE - LSE Delayed Price. Currency in GBp
-0.033 (-0.368%)
As of 8:48AM BST. Market open.
Stock chart is not supported by your current browser
Previous Close8.970
Bid8.900 x 2513500
Ask8.950 x 11600000
Day's Range8.913 - 9.100
52 Week Range3.000 - 11.500
Avg. Volume8,360,050
Market Cap277.24M
PE Ratio (TTM)-22.34
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters3 months ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.

  • We're sorry this is all we were able to find about this topic.